PKTX ProtoKinetix, Inc.
Distress ·
The notice also says its 2025 Form 10-K and its March 31, 2026 Form 10-Q have not been filed. The company cites delays in finishing its financial statements and an auditor review.
ProtoKinetix appointed Keith Brunt as a director and president and added Michael Jones and Jason Lamp to its board on June 17, 2026, after a March 31, 2026 resignation.
ProtoKinetix, Incorporated is a research and development stage biotechnology company focused on scientific medical research of AFGPs (anti-freeze glycoproteins), which it trademarks as AAGPs. The company says it is directing major efforts toward the practical side of commercial validation, and that commercial applications for AAGPs in large markets such as targeted health care solutions are numerous. It is working with researchers, business leaders, advisors and commercial entities to bring AAGP to market. ProtoKinetix was incorporated in Nevada on December 23, 1999 as RJV Network, Inc., originally to develop an internet-based commercial real estate listing site. In July 2003 it took an assignment of license from BioKinetix Research, Incorporated for proprietary technologies to create and commercialize superantibodies. In June 2023 it announced the submission of a research paper on islet-like cells differentiated from patient-derived iPSCs for the treatment and eventual cure of Type-1 Diabetes. The company has no revenues and says it will need to increase its research and development funding, which is limited by its ability to raise money.
| Product or program | What it is | Stage |
|---|---|---|
| AAGP | Anti-aging glycoprotein molecule for targeted health care applications | Research and development stage |
| Islet-like cells for Type-1 Diabetes | Islet-like cells differentiated from patient-derived iPSCs, for diabetes research | Research paper submitted June 2023 |
Our latest story on this, dated Aug 14, 2026: "ProtoKinetix files late-filing notice for its June 30, 2026 quarterly report". The story links the filing or release it is based on. Read the story.
ProtoKinetix, Inc. trades under the ticker PKTX on OTC.
ProtoKinetix, Inc. is listed on OTC.
The SEC Central Index Key (CIK) for ProtoKinetix, Inc. is 1128189. Its filings are on SEC EDGAR.
411,630,152 shares as of 2026-09-02, per the cover page of its 10-K filed 2026-09-03.
Our directory records ProtoKinetix, Inc. under United States.
Our directory classifies ProtoKinetix, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ProtoKinetix, Inc. is US7437221002.
aibio.space lists ProtoKinetix, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
ProtoKinetix, Incorporated is a research and development stage biotechnology company focused on scientific medical research of AFGPs (anti-freeze glycoproteins), which it trademarks as AAGPs. The company says it is directing major efforts toward the practical side of commercial validation, and that commercial applications for AAGPs in large markets such as targeted health care solutions are numerous.
AAGP: Anti-aging glycoprotein molecule for targeted health care applications Stage: Research and development stage.
Islet-like cells for Type-1 Diabetes: Islet-like cells differentiated from patient-derived iPSCs, for diabetes research Stage: Research paper submitted June 2023.
ProtoKinetix, Inc. reported a net loss of $393,650 for the fiscal year ended Dec 31, 2025, and used $135,377 of cash in operations, per its annual report to the SEC.
$106,613 in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio